Clinical Trials CFZ533

INNODIA is now collaborating with Novartis Pharmaceuticals on a study to evaluate the safety of the investigational drug CFZ533 (Iscalimab) in young adult and pediatric patients with recent onset type 1 diabetes. The study will evaluate whether CFZ533 can protect the remaining pancreatic beta cells. The study is now ongoing in Belgium, Italy, and the UK, and will be opening in other European countries soon.

For more Information

Please download the PDF below:

Other Innodia Trials:

How to Participate: